Zdrowie i gospodarka · 19/11/1998

FDA Proposes Revisions to Bioavailability and Bioequivalence Regulations and Abbreviated Applications

The Food and Drug Administration (FDA) is proposing to revise its regulations on bioavailability and bioequivalence and on the content and format of an abbreviated application to reflect current FDA policy and to correct certain typographical and inadvertent errors, aiming to enhance the accuracy and clarity of the regulations.